Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageApril 20 2018

A Class 4 medicines defect alert has been issued relating to Inhixa (enoxaparin sodium) solution for injection, made by Techdow Europe AB.

 The medicines regulator, the MHRA, has issued the ‘caution in use’ alert following reports of “rare cases of premature self-activation of the safety device in unused, unopened pre-filled Inhixa syringes.”

The alert lists the following strengths of Inhixa:

  • 2,000 IU (20 mg) in 0.2 mL;
  • 4,000 IU (40 mg) in 0.4 mL;
  • 6,000 IU (60 mg) in 0.6 mL;
  • 8,000 IU (80 mg) in 0.8 mL;
  • 10,000 IU (100 mg) in 1.0 mL.

Pharmacists are being asked to visually check all Inhixa syringes (without opening the syringe blister) before dispensing to check if they are affected by the self-activation defect. This is illustrated on the Direct Healthcare Professional Communication (DHCP). 

Further information is available from Techdow Pharma England Ltd on 01271 334 609.

MHRA statement          
Techdow Direct Healthcare Professional Communication             

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...